Log in

NASDAQ:CRNX - Crinetics Pharmaceuticals Stock Price, Forecast & News

$22.61
-0.97 (-4.11 %)
(As of 02/25/2020 04:48 AM ET)
Today's Range
$22.00
Now: $22.61
$23.69
50-Day Range
$21.44
MA: $23.21
$26.46
52-Week Range
$14.33
Now: $22.61
$28.81
Volume33,600 shs
Average Volume64,694 shs
Market Capitalization$547.66 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRNX
CUSIPN/A
CIKN/A
Phone858-450-6464

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.43 million
Book Value$6.67 per share

Profitability

Net Income$-27,110,000.00

Miscellaneous

Employees47
Market Cap$547.66 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.


Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by $0.03. The company had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.33 million. View Crinetics Pharmaceuticals' Earnings History.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Crinetics Pharmaceuticals.

What price target have analysts set for CRNX?

3 brokers have issued 1-year price objectives for Crinetics Pharmaceuticals' shares. Their forecasts range from $35.00 to $40.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $37.33 in the next twelve months. This suggests a possible upside of 65.1% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.

What is the consensus analysts' recommendation for Crinetics Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.

What are Wall Street analysts saying about Crinetics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Crinetics Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. " (1/22/2020)
  • 2. HC Wainwright analysts commented, "Valuation; reiterate Buy rating. Our $35 price target for Crinets is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (4/16/2019)

Has Crinetics Pharmaceuticals been receiving favorable news coverage?

News articles about CRNX stock have trended neutral on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Crinetics Pharmaceuticals.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a decrease in short interest in January. As of January 15th, there was short interest totalling 1,840,000 shares, a decrease of 9.8% from the December 31st total of 2,040,000 shares. Based on an average daily trading volume, of 56,600 shares, the short-interest ratio is presently 32.5 days. Currently, 13.2% of the company's shares are sold short. View Crinetics Pharmaceuticals' Current Options Chain.

Who are some of Crinetics Pharmaceuticals' key competitors?

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the folowing people:
  • Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
  • Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
  • Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
  • Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), 5AM Venture Management LLC (9.75%), Janus Henderson Group PLC (2.02%), State Street Corp (0.94%), Victory Capital Management Inc. (0.81%) and Victory Capital Management Inc. (0.79%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Matthew K Fust, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Crinetics Pharmaceuticals.

Which major investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Victory Capital Management Inc., Victory Capital Management Inc. and Janus Henderson Group PLC. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View Insider Buying and Selling for Crinetics Pharmaceuticals.

Which major investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was bought by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, State Street Corp, California Public Employees Retirement System, UBS Group AG, FMR LLC, Geode Capital Management LLC, Barclays PLC and Rockefeller Capital Management L.P.. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive and Vivo Capital Viii, Llc. View Insider Buying and Selling for Crinetics Pharmaceuticals.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $22.61.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $547.66 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is http://www.crinetics.com/.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]


MarketBeat Community Rating for Crinetics Pharmaceuticals (NASDAQ CRNX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: What is the Beige Book?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel